Wide Ranks

BCAB

BioAtla, Inc.

1.64

Top Statistics
Market Cap 79 M Forward PE -1.25 Revenue Growth 0.00 %
Current Ratio 3.11 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2820 Enterprise / Revenue 2.18 Price To Sales Trailing12 Months 7.21
Profitability
Profit Margins 0.00 % Operating Margins -102.46 %
Balance Sheet
Total Cash 56 M Total Cash Per Share 1.17 Total Debt 1 M
Total Debt To Equity 5.45 Current Ratio 3.11 Book Value Per Share 0.4750
All Measures
Short Ratio 408.00 % Message Board Id finmb_105291463 Fax 858 558 0709
Shares Short Prior Month 5 M Return On Equity -1.39 City San Diego
Uuid 35fd9bcd-d23c-3ada-beff-01d8b746a34b Previous Close 1.57 First Trade Date Epoch Utc 1 B
Book Value 0.4750 Beta 1.02 Total Debt 1 M
Volume 298790 Price To Book 3.45 Fifty Two Week Low 1.14
Total Cash Per Share 1.17 Total Revenue 11 M Shares Short Previous Month Date 1 B
Target Median Price 13.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -102.46 % Target Mean Price 10.67 Net Income To Common -81817000
Short Percent Of Float 0.0957 Implied Shares Outstanding 48 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 56 M Next Fiscal Year End 1 B Revenue Per Share 0.2280
Held Percent Insiders 0.1075 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.57 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.88 Open 1.60
Free Cashflow -56728876 State CA Dividend Yield 0.00 %
Return On Assets -0.5047 Time Zone Short Name EST Trailing Eps -1.70
Day Low 1.57 Address1 11085 Torreyana Road Shares Outstanding 48 M
Price Hint 4 Target High Price 14.00 Website https://www.bioatla.com
52 Week Change -0.0734 Average Volume 1 M Forward Eps -1.47
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 290.40 %
Is_sp_500 False Regular Market Day High 1.67 Profit Margins 0.00 %
Debt To Equity 5.45 Fifty Two Week High 4.02 Day High 1.67
Shares Short 4 M Regular Market Open 1.60 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2.18 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0856 Operating Cashflow -85075000 Currency USD
Time Zone Full Name America/New_York Market Cap 79 M Is_nasdaq_100 False
Zip 92121 Quote Type EQUITY Industry Biotechnology
Long Name BioAtla, Inc. Regular Market Day Low 1.57 Held Percent Institutions 0.4285
Current Price 1.64 Enterprise To Ebitda -0.2820 Financial Currency USD
Current Ratio 3.11 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 37 M Two Hundred Day Average 2.10
Enterprise Value 24 M Price To Sales Trailing12 Months 7.21 Forward PE -1.25
Regular Market Volume 298790 Ebitda -85170000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.

It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.

The company was founded in 2007 and is headquartered in San Diego, California.